-
Je něco špatně v tomto záznamu ?
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
AC. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor, R. Letestu, J. Nomdedeu, C. Palacio, O. Stehlikova, KA. Kreuzer, S. Liptrot, D. O'Brien, RM. de Tute, I. Marinov, M. Hauwel, M. Spacek, J. Dobber, AP. Kater, P. Gambell, A. Soosapilla, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
PubMed
26639181
DOI
10.1038/leu.2015.313
Knihovny.cz E-zdroje
- MeSH
- CD antigeny metabolismus MeSH
- chronická lymfatická leukemie patologie terapie MeSH
- dospělí MeSH
- imunofenotypizace MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- prognóza MeSH
- průtoková cytometrie normy MeSH
- reziduální nádor diagnóza genetika metabolismus MeSH
- staging nádorů MeSH
- vysoce účinné nukleotidové sekvenování metody MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
3rd Medical Department Paracelsus Medical University Salzburg Austria
Adaptive Biotechnologies Seattle WA USA
Department of Haematology Royal North Shore Hospital Sydney Australia
Department of Hematology Academic Medical Centre Amsterdam Netherlands
Divisions of Hematology and Hematopathology Mayo Clinic Rochester MN USA
General University Hospital Prague Czech Republic
Hematology and Flow Cytometry Laverty Pathology Sydney Australia
HMDS St James's Institute of Oncology Leeds UK
Hôpital Avicenne Assistance Publique Hôpitaux de Paris Bobigny France
Hospital Clínic IDIBAPS Barcelona Spain
Hospital de la Santa Creu i Sant Pau Barcelona Spain
Hospital Universitari Vall d'Hebron Barcelona Spain
Institute of Hematology and Blood Transfusion University Hospital Prague Prague Czech Republic
IRCCS San Raffaele Scientific Institute Milano Italy
IRCCS San Raffaele Scientific Institute Milano Italy Università Vita Salute San Raffaele Milan Italy
Leeds Institute of Cancer and Pathology University of Leeds Leeds UK
MD Anderson Cancer Center Houston TX USA
Moores Cancer Center University of California San Diego La Jolla CA USA
National Cancer Institute National Institutes of Health Bethesda MD USA
Ohio State University Medical Center Columbus OH USA
Peter MacCallum Cancer Centre Melbourne Australia
Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool UK
St James Hospital Dublin Ireland
Un1iversity of Pittsburgh Pittsburgh PA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027864
- 003
- CZ-PrNML
- 005
- 20161025111758.0
- 007
- ta
- 008
- 161005s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2015.313 $2 doi
- 024 7_
- $a 10.1038/leu.2015.313 $2 doi
- 035 __
- $a (PubMed)26639181
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rawstron, A C $u HMDS, St James's Institute of Oncology, Leeds, UK.
- 245 12
- $a A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study / $c AC. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor, R. Letestu, J. Nomdedeu, C. Palacio, O. Stehlikova, KA. Kreuzer, S. Liptrot, D. O'Brien, RM. de Tute, I. Marinov, M. Hauwel, M. Spacek, J. Dobber, AP. Kater, P. Gambell, A. Soosapilla, G. Lozanski, G. Brachtl, K. Lin, J. Boysen, C. Hanson, JL. Jorgensen, M. Stetler-Stevenson, C. Yuan, HE. Broome, L. Rassenti, F. Craig, J. Delgado, C. Moreno, F. Bosch, A. Egle, M. Doubek, S. Pospisilova, S. Mulligan, D. Westerman, CM. Sanders, R. Emerson, HS. Robins, I. Kirsch, T. Shanafelt, A. Pettitt, TJ. Kipps, WG. Wierda, F. Cymbalista, M. Hallek, P. Hillmen, E. Montserrat, P. Ghia,
- 520 9_
- $a In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a CD antigeny $x metabolismus $7 D015703
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $x normy $7 D005434
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $7 D016130
- 650 _2
- $a chronická lymfatická leukemie $x patologie $x terapie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a reziduální nádor $x diagnóza $x genetika $x metabolismus $7 D018365
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fazi, C $u IRCCS San Raffaele Scientific Institute, Milano, Italy.
- 700 1_
- $a Agathangelidis, A $u IRCCS San Raffaele Scientific Institute, Milano, Italy. $7 gn_A_00002102
- 700 1_
- $a Villamor, N $u Hospital Clínic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Letestu, R $u Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
- 700 1_
- $a Nomdedeu, J $u Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 700 1_
- $a Palacio, C $u Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Stehlikova, O $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kreuzer, K-A $u University Hospital, Cologne, Germany.
- 700 1_
- $a Liptrot, S $u St James Hospital, Dublin, Ireland.
- 700 1_
- $a O'Brien, D $u St James Hospital, Dublin, Ireland.
- 700 1_
- $a de Tute, R M $u HMDS, St James's Institute of Oncology, Leeds, UK.
- 700 1_
- $a Marinov, I $u Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.
- 700 1_
- $a Hauwel, M $u University Hospital Geneva, Geneva, Switzerland.
- 700 1_
- $a Spacek, M $u General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Dobber, J $u Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
- 700 1_
- $a Kater, A P $u Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
- 700 1_
- $a Gambell, P $u Peter MacCallum Cancer Centre, Melbourne, Australia.
- 700 1_
- $a Soosapilla, A $u Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.
- 700 1_
- $a Lozanski, G $u Ohio State University Medical Center, Columbus, OH, USA.
- 700 1_
- $a Brachtl, G $u 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria. Experimental and Clinical Cell Therapy Institute, Spinal Cord and Tissue Regeneration Center, Paracelsus Medical University, Salzburg, Austria.
- 700 1_
- $a Lin, K $u Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
- 700 1_
- $a Boysen, J $u Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- 700 1_
- $a Hanson, C $u Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- 700 1_
- $a Jorgensen, J L $u MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Stetler-Stevenson, M $u National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- 700 1_
- $a Yuan, C $u National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- 700 1_
- $a Broome, H E $u Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- 700 1_
- $a Rassenti, L $u Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- 700 1_
- $a Craig, F $u Un1iversity of Pittsburgh, Pittsburgh, PA, USA.
- 700 1_
- $a Delgado, J $u Hospital Clínic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Moreno, C $u Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 700 1_
- $a Bosch, F $u Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Egle, A $u 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
- 700 1_
- $a Doubek, M $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pospisilova, S $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Mulligan, S $u Department of Haematology, Royal North Shore Hospital, Sydney, Australia.
- 700 1_
- $a Westerman, D $u Peter MacCallum Cancer Centre, Melbourne, Australia.
- 700 1_
- $a Sanders, C M $u Adaptive Biotechnologies, Seattle, WA, USA.
- 700 1_
- $a Emerson, R $u Adaptive Biotechnologies, Seattle, WA, USA.
- 700 1_
- $a Robins, H S $u Adaptive Biotechnologies, Seattle, WA, USA.
- 700 1_
- $a Kirsch, I $u Adaptive Biotechnologies, Seattle, WA, USA.
- 700 1_
- $a Shanafelt, T $u Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- 700 1_
- $a Pettitt, A $u Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
- 700 1_
- $a Kipps, T J $u Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- 700 1_
- $a Wierda, W G $u MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Cymbalista, F $u Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
- 700 1_
- $a Hallek, M $u University Hospital, Cologne, Germany.
- 700 1_
- $a Hillmen, P $u Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
- 700 1_
- $a Montserrat, E $u Hospital Clínic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Ghia, P $u IRCCS San Raffaele Scientific Institute, Milano, Italy. Università Vita-Salute San Raffaele, Milan, Italy.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 30, č. 4 (2016), s. 929-36
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26639181 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161025112211 $b ABA008
- 999 __
- $a ok $b bmc $g 1166178 $s 952494
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 30 $c 4 $d 929-36 $e 20151207 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20161005
